Microbot Medical Inc. (NASDAQ:MBOT) Short Interest Up 21.8% in February

Microbot Medical Inc. (NASDAQ:MBOT) was the target of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 7,358,340 shares, a growth of 21.8% from the January 29th total of 6,040,735 shares. Currently, 11.5% of the shares of the company are short sold. Based on an average daily volume of 3,709,221 shares, the short-interest ratio is currently 2.0 days. Based on an average daily volume of 3,709,221 shares, the short-interest ratio is currently 2.0 days. Currently, 11.5% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several analysts recently weighed in on MBOT shares. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research note on Friday, November 28th. B. Riley Financial initiated coverage on Microbot Medical in a report on Tuesday, February 10th. They set a “buy” rating for the company. Finally, Roth Mkm initiated coverage on Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Microbot Medical presently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Microbot Medical Stock Down 1.6%

Shares of MBOT opened at $2.41 on Friday. Microbot Medical has a 12-month low of $1.34 and a 12-month high of $4.67. The firm has a market capitalization of $161.86 million, a price-to-earnings ratio of -5.36 and a beta of 1.22. The stock’s 50-day moving average price is $2.09 and its 200 day moving average price is $2.55.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Microbot Medical by 14.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock valued at $7,148,000 after buying an additional 292,923 shares during the period. CIBC Private Wealth Group LLC boosted its position in shares of Microbot Medical by 1.8% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock valued at $2,960,000 after acquiring an additional 26,000 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in shares of Microbot Medical during the 3rd quarter valued at about $4,435,000. Heights Capital Management Inc. bought a new stake in Microbot Medical in the third quarter valued at about $2,693,000. Finally, Geode Capital Management LLC raised its position in Microbot Medical by 54.4% in the fourth quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock worth $1,524,000 after purchasing an additional 268,609 shares in the last quarter. 16.30% of the stock is owned by institutional investors.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.